Member Info for Scaffers

I had to phone Barclays to vote on the share offer. Only a yes or a no option available.

Older A320 family aircraft were powered by either the IAE V2500 family, a collaboration between RR, Pratt & Witney, Japanese Aero Engines and MTU of the CFM 56-5 a collaboration between Safran Aircraft Engines (formerly known as Snecma), and GE Aerospace.

From Wikopedia : The Airbus A320neo family is an incremental development of the A320 family of narrow-body airliners produced by Airbus. The A320neo family (neo being Greek for "new", as well as an acronym for "new engine option") is based on the previous A319, A320, and A321 (enhanced variant), which was then retrospectively renamed the A320ceo family (ceo acronym for "current engine option").

Re-engined with CFM International LEAP or Pratt & Whitney PW1000G engines and fitted with sharklets wingtip devices as standard, the A320neo is 15% to 20% more fuel efficient than prior models, the A320ceo. It was launched on 1 December 2010, made its first flight on 25 September 2014 and was introduced by Lufthansa on 25 January 2016.

By 2019, the A320neo had a 60% market share against the competing Boeing 737 MAX.[4] As of April 2024, a total of 10,501 A320neo family aircraft had been ordered by more than 130 customers, of which 3,330 aircraft had been delivered. The global A320neo fleet had completed more than 7.35 million flights over 14.67 million block hours with one hull loss being an airport-safety related accident.

@badmashy The open offer is only available to those who haven't participated in the REX offer.

I've just spoken to them and gave them the RNS number - they know about it now and it should go live in the next couple of days. :)

I've just spoken to Barclays and gave them the open offer RNS number. It should go live in the next couple of days.

I'm in the same boat. We need to get in touch with them.

Only 1 sell 133,330 @2p 12.04.42 showing in Thompson Reuters. 100k sell @7.02p 12.04.12

My chart shows a target price of 16.97p with the next resistance at 21p

Someone was confident enough to buy 250k @ 24.2p on Friday. Went through after hours at 16.34 :)

RiverFort is Pleased to Announce That It Has Arranged an Equity Prepayment Facility for Committed Prepayments up to Aggregate £5 Million (the "Facility") with Genedrive plc (LSE: GDR) - Business Wire

04-Apr-2023 12:16:00RIVERFORT-GLOBAL

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230404:nBwnnVH0a&default-theme=true

RiverFort is Pleased to Announce That It Has Arranged an Equity Prepayment
Facility for Committed Prepayments up to Aggregate £5 Million (the
"Facility") with Genedrive plc (LSE: GDR)

RiverFort is pleased to announce that it has arranged an Equity Prepayment
Facility for up to £5 million (the "Facility") with Genedrive plc (LSE: GDR)
(“Genedrive” or the “Company”), the point of care molecular
diagnostics company, with an initial drawn amount of £2 million and committed
capital advances of up to £3 million in 10 monthly instalments of £300,000
from 30 May 2023 which may be drawn down by the Company at its election.

The Facility and the Company's existing cash resources will be directed
towards the commercialisation of the Company's Antibiotic Induced Hearing Loss
test, Genedrive(®) MT-RNR1 ID Kit ("AIHL test") and enhancing the
Genedrive(®) platform through the validation and verification of the
Company's CYP2C19 test, Genedrive(®) CYP2C19 ID Kit ("CYP2C19 test") as well
as providing additional working capital.

Genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and robust point
of need molecular diagnostics platform for the diagnosis of infectious
diseases and for use in patient stratification (genotyping), pathogen
detection and other indications. The company are currently developing a
genetic test for CYP2C19 metaboliser status.

The Genedrive(®)MT-RNR1 ID Kit, selected as 1 of the 10 EVA pilot projects,
is the world's first commercial point-of-care genetic test for emergency care.
It helps to avoid irreversible lifelong hearing loss in specific infants
exposed to aminoglycosides by rapidly detecting the m.1555A>G gene variant
that can cause lifelong deafness, allowing for alternative antibiotics to be
prescribed.

David Budd, CEO of Genedrive commented:

“The Directors have assessed a number of financing options for the Company
including an equity raise but believe that the Facility is the best option
available to the Company at the present time in order to further fund the
Company's progress while also taking consideration of the investor shareholder
base. Further, the Directors believe that a combination of the possibility of
positive future news flow around the Company's two main assays as well as the
potential for reasonable levels of liquidity in the Company's ordinary shares
make the Facility the most attractive form of financing for the Company at the
current time.”

RiverFort Glo

Fingers crossed bigAl. It's been a while!

I've got Livedata filtered.

I'm with Barclays too, same situation. I've not asked them but I think they become ISA eligable when they'ye converted to full share on 7th Nov or thereabouts???

Taskmaster, it's no different to people who own more than one car. You can only drive one at a time. You just choose the one that fits your planned journey best.

Still no trades showing at 08.36. Reuters Live feed!!!

From the same article : His Genedrive trial was considered so important that it was allowed to continue during the pandemic when many other research trials were halted. His team is already working with genedrive plc on a similar rapid bedside test for stroke patients – to detect the one in 10 patients whose DNA makes them unable to metabolise clopidogrel the common anti-platelet medication, and therefore have significantly worse outcomes

Both shown as sells on Thompson Reuters

29p

I think most people know that the traditional high pressure tanks are either cylindrical or round Bilbo. Any other shape would have weak spots which need to be reinforced, making them heavier.